“ China’s robust medical regulatory framework and vibrant innovation ecosystem demonstrate incredible potential in realizing the Healthy China 2030 initiative ,” said Li Zili, vice president and head of Asia Pacific R&D, Janssen Research & Development, LLC.,
A key part of this effort is using data science to transform how we discover and develop drugs, bringing transformative medicines to patients in China and around the world .”
The use of real-world evidence (RWE) in clinical development has been the focus of several key policies released by the Chinese government since early 2020. It has also been encouraged in the Bo'ao Lecheng International Medical Pilot Zone in Hainan Province, where the use of drugs approved in the US, Europe or Japan, but not yet in China, has yielded valuable results for Chinese patients.
“ We see great potential in China to develop and conduct RWE studies in a more systematic and rigorous manner, using high-quality data and standardized infrastructure ,” said Najat Khan, chief data scientist nepal telegram number database and global head of R&D strategy and operations, Janssen R&D.
“ At Janssen R&D, we are deeply invested in the potential of data science to improve R&D efficiency and drive real impact .”
Last week, the Hong Kong government added four South African countries and 12 other countries to its high-risk list as Omicron cases rose around the world.
On December 1, it was announced that a 38-year-old man who arrived in Hong Kong from Qatar on November 24 was stuck in the restricted transit area at Hong Kong International Airport for four days due to a visa-related issue and tested positive for Omicron in a test before his departure on November 28.